To date, germline heterozygous mutations at the single nucleotide level within the promoter of the PTEN gene have been identified in patients with CS and/or BRRS diagnosed with breast, thyroid, and/or endometrial cancer. The gene discussed is PTEN; the disease is endometrial cancer.